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Obesity has become a global health problem and it is linked to a higher risk of diseases and metabolic disorders such as diabetes,
cardiovascular disease, and cancer. The adipose tissue plays an important role in monitoring and controlling whole-body metabolism
by secreting a variety of bioactive molecules such as adiponectin. Deﬁciencies of this hormone can cause type II diabetes and cardiovas-
cular disease both in mice and in humans. Therefore, adiponectin is an attractive molecule to use in human therapy, particularly in a
recombinant form. The source of recombinant adiponectin could be the expression of full-length adiponectin either in Escherichia coli,
or in baculovirus. In this work we express and purify human adiponectin in both systems. The adiponectin produced by baculovirus was
found to be 10 times more active as far as oligomerization and human pre-adipocyte diﬀerentiation are concerned, when compared with
adiponectin produced by E. coli. We presume that adiponectin expressed in baculovirus has post-translation modiﬁcations not made by
bacteria which may be responsible for these diﬀerences in activity. This renders adiponectin produced by baculovirus a better candidate
for the treatment of type II diabetes and cardiovascular disease.
 2008 Elsevier Inc. All rights reserved.
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trial countries, is associated with increased cardiovascular
mortality and morbidity [1–4,15]. Visceral fat accumulation
is correlated to the development of cardiovascular disease
and obesity-related disorders such as type II diabetes melli-
tus, hyperlipidemia, and hypertension [5]. The coexistence of
these diseases has been termed the metabolic syndrome and
insulin resistance is a key feature of this syndrome [4]. Adi-
pose tissue plays major functions in energy homeostasis,
lipid metabolism, and insulin actions by regulating the secre-
tion of diverse factors such as leptin, adiponectin, tumor
necrosis factor-a (NNF-a)1, plasminogen activator inhibi-
tor-1, and various cytokines [5]. Adipocyte diﬀerentiation1046-5928/$ - see front matter  2008 Elsevier Inc. All rights reserved.
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weight; MMW, middle molecular weight; HMW, high molecular weight.is critical for metabolic homeostasis and nutrient signaling.
Treatment of pre-adipocytes with insulin, glucocorticoids,
and cAMP inducers, such as adiponectin, stimulates a tran-
scriptional cascade resulting in a gene expression proﬁle spe-
ciﬁc for adipocyte function [6]. Several critical transcription
factors and cross-talk between those factors have been well
deﬁned, including the CCAAT/enhancer-binding proteins
(C/EBP) and peroxisome proliferators-activated receptor-c
(PPAR-c). The phosphoinositide-3-kinase (PI3K)/Akt path-
way has also been shown to be critically involved in adipo-
cyte diﬀerentiation. The activity of PI3K and Akt kinases
is increased during the diﬀerentiation process [7], and consti-
tutive activation of Akt leads to spontaneous diﬀerentiation
without hormone stimulation.
Adiponectin/Acrp30 is present in human plasma and
breast milk and is critical in the control of whole-body
metabolism, particularly by enhancing insulin sensitivity
in muscle and liver, and by increasing fatty acid oxidation
in muscle [8–12]. Adiponectin is a 244 amino acid protein
composed of four distinct domains: A signal peptide at
M. do Carmo Avides et al. / Protein Expression and Puriﬁcation 59 (2008) 122–126 123the N-terminus, a short variable region, a collagenous
domain, and a C-terminal globular domain homologous
to C1q. The metabolic and insulin-sensitizing eﬀects of
adiponectin can be at least partially explained by their
direct activation of AMPK, leading to increased fatty acid
oxidation and the prevention of triacylglycerol accumula-
tion and lipotoxicity in these tissues [12,14].
Adiponectin is secreted speciﬁcally from adipocytes:
Diﬀerent complexes build up from a low molecular weight
(LMW) trimer form, to middle molecular weight (MMW)
hexamers consisting of two trimers, to high molecular
weight (HMW) forms consisting of up to 18 molecules
[13]. Glucose tolerance is better correlated with the levels
of HMW complexes in the serum than with total adiponec-
tin [13]. Improvement of insulin sensitivity in treated
human diabetics was associated with an increase in the
ratio of plasma HMW adiponectin to total adiponectin lev-
els. A relative increase in the HMW/MMW ratio and a
reduced LMW adiponectin were also observed after weight
reduction. Mutations of the adiponectin gene, leading to
alterations in the formation of HMW complexes, are asso-
ciated with type II diabetes and extremely low circulating
levels of HMW adiponectin. These studies suggest that
HMW adiponectin is a better biomarker of insulin resis-
tance than is the commonly used measure of total adipo-
nectin [13]. Reduced adiponectin levels associated with
gene polymorphisms have been linked to metabolic syn-
drome, type II diabetes, and coronary artery disease.
Since administration of adiponectin to persons suﬀering
from these diseases could potentially ameliorate their symp-
toms we thought of producing the protein in baculovirus as
this system executes eukaryotic post-translation modiﬁca-
tions, and in Escherichia coli, for bacteria can express a lar-
ger amount of protein.We found baculovirus adiponectin to
be more active, particularly in what concerns human pre-
adipocyte diﬀerentiation. Presumably, the protein is more
active because it can form larger multimers than its E. coli
counterpart, thus, baculovirus adiponectin is a better candi-
date to use in future human therapy of type II diabetes,
obesity, atherosclerosis, and hypertension.
Materials and methods
Reagents
Chemicals were from Sigma-Aldrich (St. Louis, MO).
Cells were obtained from ECACC and cell culture and
transfection reagents were from Invitrogen (Carlsbad,
CA) as was pFastBac and sf9 cells. pET 25 was purchased
from Novagen (Merck Biosciences, Nottingham). Ni–NTA
resin, plasmid miniprep kits, and his-tag puriﬁcation sys-
tems were from Qiagen (Hilden, Germany). Enzymes for
molecular biology were obtained from Promega (Madison,
WI) or New England Biolabs (Ipswich, MA). The human
adiponectin cDNA was purchased from Open Biosystems
(Hunstville, AL). Electrophoresis equipment was from
Bio-Rad Laboratories (Hercules, CA).Primary human adipocyte culture
Primary human adipocytes from the ECACC were cul-
tured in DMEM (Gibco) supplemented with 33 lM biotin,
17 lM pantothenate, 10 lg/ml transferrin, 2 mM L-gluta-
mine, 100 U/ml penicillin, and 100 lg/ml streptomycin.
Cultures were incubated at 37 C with 5% carbon dioxide.Bacterial expression of adiponectin
Human adiponectin cDNA was cloned into pET25b and
transformed into BL21(DE3)pLys-S cells for inducible
expression. Expression cultures (10 ml) were inoculated
from an overnight starter culture and allowed to reach an
A600 of 0.6 before induction with 1 mM IPTG for 3 h at
37 C. Cells were either resuspended in SDS–PAGE sample
buﬀer or extracted with a Qiagen non-denaturing lysis buf-
fer. Samples were cleared by centrifugation at 16,000g for
20 min at 4 C and analyzed by SDS or native PAGE.Baculovirus expression of adiponectin
Human adiponectin cDNA was cloned in pFastBac
(Invitrogen) after insertion of a his-tag sequence in the vec-
tor. This construct was transfected into sf9 cells in culture,
following the protocols provided by the manufacturer.
Adiponectin expression was followed by SDS–PAGE of
the cells and the culture supernatant.Puriﬁcation of recombinant adiponectin
Adiponectin–His was puriﬁed by aﬃnity chromatogra-
phy nickel columns using the materials, columns, and pro-
tocols provided by Qiagen.Analysis of monomeric and multimeric adiponectin
Adiponectin multimers were separated by PAGE,
according to protocols provided by Bio-Rad. Gels were
stained with Coomassie blue R-250.Results
Expression of human adiponectin in E. coli and baculovirus
Human adiponectin cDNA was purchased from Open
Biosystems and subcloned into the E. coli expression vector
pET25 (Novagen) in frame with the histidine tag. Expres-
sion in bacteria was induced with either 0.5 or 1 mM IPTG
(Fig. 1A, lanes 3 and 4). Both IPTG concentrations were
found to be eﬀective for adiponectin expression (Fig. 1A)
irrespective of the induction time (results not shown).
Induced cells were collected by centrifugation and human
adiponectin was puriﬁed on Ni–NTA columns (Qiagen)
using a native procedure (see Materials and methods).
The protein was deemed pure by SDS–PAGE followed
Fig. 2. Contrast phase microscopy images of human pre-adipocytes and
adipocytes in culture (ampliﬁcation—400). (A) Pre-adipocytes, (B)
Adipocytes diﬀerentiated by addition of 0.5 lg/ml adiponectin expressed
in E. coli, (C and D) Adipocytes diﬀerentiated by addition of adiponectin
produced in baculovirus (C, 0.1 lg; D, 0.5 lg).
Fig. 1. Expression of adiponectin in E. coli (A) and baculovirus (B)
assessed by SDS–PAGE. (A) Lane 1—Molecular weight markers; lane 2—
total extract from E. coli prior to induction; lanes 3 and 4—induction of
adiponectin expression by 0.5 or 1 mM IPTG, respectively; lane 5—
puriﬁed recombinant adiponectin. (B) Lane 1—Molecular weight markers;
lanes 2 and 3—expression of adiponectin in baculovirus after 36 h or 72 h
Sf9 cell infection (respectively); lane 4—puriﬁed adiponectin from bacu-
lovirus. For cell extracts 10 ll of sample per lane was used, whereas 1 lg of
puriﬁed protein was loaded. Gels were stained with Coomassie Blue-R
250.
124 M. do Carmo Avides et al. / Protein Expression and Puriﬁcation 59 (2008) 122–126by Coomassie staining (Fig. 1A, lane 5). The yield was typ-
ically 10–20 mg of protein per 250 mL of culture.
The same cDNA was subcloned into pFastBac (Invitro-
gen) following insertion of a his-tag sequence into the vec-
tor. Positive recombinant bacmids were selected and used
to transfect Sf9 cells in culture following the protocols pro-
vided by Invitrogen. The virus was ampliﬁed by Sf9 cell
infection and collection of the culture supernatant. Adipo-
nectin expression was assessed by SDS–PAGE after 36 or
72 h of infection (Fig. 1B, lanes 2 and 3). The fusion (his-
tag) protein was puriﬁed from 36 h infected Sf9 culture
supernatant by aﬃnity chromatography on Ni–NTA col-
umns (Qiagen) and its purity assessed by SDS–PAGE
(Fig. 1B, lane 4). Typical yields were of 10 mg of protein
per liter of Sf9 cell culture.
Diﬀerentiation of pre-adipocytes
Adiponectin has the ability to induce diﬀerentiation of
pre-adipocytes into mature adipocytes as upon binding toits receptor it stimulates a transcriptional cascade resulting
in a gene expression proﬁle speciﬁc for adipocyte function.
Several critical transcription factors and cross-talk between
those factors have been well deﬁned, including the
CCAAT/enhancer-binding proteins (C/EBP) and peroxi-
some proliferators-activated receptor-gamma (PPAR-c).
The phosphoinositide-3-kinase (PI3K)/Akt pathway has
also been shown to be critically involved in adipocyte
diﬀerentiation.
In order to investigate the activity of E. coli and baculo-
virus produced adiponectin we chose to grow human pre-
adipocytes (obtained from the ECACC) and check the abil-
ity of the protein to induce its diﬀerentiation. Diﬀerentia-
tion was estimated by viewing the morphology of the
cells (Fig. 2) which changes from a ﬁbroblast-like ﬁgure
(Fig. 2A) to round cells with lipid droplets stained by neu-
tral red (Fig. 2B–D). Cells were then counted in a Neu-
bauer chamber.
Adiponectin produced in baculovirus was far more
active in promoting diﬀerentiation than adiponectin pro-
duced in E. coli (Figs. 2B–D and 3) as lower concentrations
of the protein were able to induce full maturation of pre-
adipocytes. To achieve the same degree of diﬀerentiation,
10 more E. coli protein was needed, presumably due to
the post-translation modiﬁcations a baculovirus system is
able to carry on (Fig. 3).Analysis of adiponectin multimers
As adiponectin exists in vivo as homomultimers and the
HMW (high molecular weight) form is more active in what
concerns conferring insulin sensitivity to cells [16], we
sought for the multimeric forms of both kinds of adiponec-
tin in solution. Fig. 4 depicts a gel where adiponectin
homomultimers are separated by PAGE. Remarkably, bac-
ulovirus adiponectin is able to form multimers up to 18
molecules in size (lane B), whereas E. coli adiponectin
forms mainly trimers (lane C). In both cases, monomeric
adiponectin is the mainly species seen. We presume that
Fig. 3. Quantiﬁcation of diﬀerentiated adipocytes after addition of puriﬁed adiponectin to pre-adipocytes in culture.
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translation modiﬁcations not possible in E. coli [16].
Discussion
Adiponectin is expressed exclusively by diﬀerentiated
adipocytes and its expression is induced during adipocyte
diﬀerentiation [3]. Plasma levels of adiponectin are reduced
in obese/diabetic mice and humans, in patients with cardio-
vascular diseases, hypertension, and metabolic syndrome
but the mechanism of reduction on the plasma adiponectin
level is not clearly understood [4]. Reduction of adiponectin
levels is one of the causes of type II diabetes as mice deﬁ-
cient for adiponectin are insulin resistant and replenishment
of a physiological dose of recombinant adiponectin to these
mice signiﬁcantly ameliorates insulin resistance [4]. More-
over, insulin resistance in lipoatrophic mice is completely
reversed by the combination of physiological doses of
adiponectin and leptin [4]. These data indicate that adipo-
nectin has a direct insulin-sensitizing action and suggest
that adiponectin and leptin are the two major insulin-sensi-
tizing hormones secreted by adipose tissue. Plasma adipo-
nectin levels are also decreased in an obese rhesus monkey
model that frequently develops type II diabetes and have
also been reported to be decreased in obese humans, and
to correlate inversely with insulin resistance [3]. Hypoadipo-
nectinemia is also commonly observed in a variety of statesfrequently associated with insulin resistance, such as cardio-
vascular disease and hypertension. Thus, administration of
adiponectin by spray aspiration or injection can potentially
help patients with these disorders.
A therapeutic target for the treatment of insulin resis-
tance, type II diabetes, the metabolic syndrome, and cardio-
vascular disease may include the upregulation of plasma
adiponectin levels (e.g. by the administration of recombi-
nant adiponectin), the upregulation of adiponectin recep-
tors, or the development of adiponectin receptors agonists.
Potentially, one could administer either adiponectin
produced in E. coli or baculovirus and so we thought of
producing and purifying the hormone in both systems.
Adiponectin is readily expressed in both, although expres-
sion in baculovirus is demanding and time-consuming.
Despite this drawback, the protein is more active as far
as pre-adipocyte maturation is concerned when expressed
in baculovirus, presumably due to the post-translation
modiﬁcations carried out in this system. It is also possible
that adiponectin expressed in E. coli is not folded correctly
and cannot self-associate. Post-translation modiﬁcations of
adiponectin, such as hydroxylation of multiple conserved
proline and lysine residues and glycosylation of hydroxyly-
sines, have been shown to exist in vivo and to be required
for recombinant adiponectin oligomerization [16]. Indeed,
we found baculovirus produced adiponectin to exist in
multimeric species similar to the ones described as active.
Fig. 4. Separation of adiponectin homomultimers on a PAGE gel. (Lane
A) Molecular weight markers; (lane B) adiponectin from baculovirus;
(lane C) adiponectin from E. coli. Ten micrograms of protein was used in
each lane. The gel was stained with Coomassie Blue R-250.
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activity and so we believe that therapeutical use of large-
scale baculovirus produced adiponectin might be beneﬁcial
for type II diabetes and cardiovascular disease.
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